Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatropin Dose Regimens in Adult GHD
NCT00570011Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 1997
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Plasminogen Activator Inhibitor-1 at 6 months and Tissue Plasminogen Activator at 6 months. Started Jun 1997; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00570011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570011.